Aurobindo Pharma USA Inc. has agreed to pay Novartis AG's generics division, Sandoz Inc., up to $1 billion for a basket of dermatology and generic oral medicines that the Swiss drugmaker is divesting as it pursues growth amid increasingly challenging forces in the generics space. With an up-front purchase price of $900 million plus up to $100 million in potential earn-outs, the deal will add about 300 products to Aurobindo's portfolio, including projects in development, as well as new U.S.-based commercial and manufacturing capabilities.